https://kstockbriefing.com
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion issued an advance notice that it plans to disclose its provisional Q1 2025 financial results (covering Jan 1, 2025 to Mar 31, 2025) on May 9, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Adherence to the Disclosure…
![[Disclosure] ALTEOGEN (196170) – Change of Market Division / 2025-04-30](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN announced that its KOSDAQ market division assignment has been changed from ‘Technology Growth Business Division’ to ‘Premier Business Division’ upon satisfying the regular qualification criteria for Premier status. The change takes effect on May 02, 2025. 📊 [Key Disclosure Details & Major Figures Summary] 📝…
Read More “[Disclosure] ALTEOGEN (196170) – Change of Market Division / 2025-04-30” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen is consolidating two of its subsidiaries (Altos Biologics and Alteogen Healthcare) into one, receiving new shares issued by the surviving entity (Altos Biologics). This is an internal organizational restructuring involving no new cash outlay, with investment amounts combined solely for accounting purposes. 📊 [Key Disclosure…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to acquire 631,712 treasury common shares worth approximately KRW 100.0B through on-market purchases to stabilize its stock price and enhance shareholder value, with plans to retire all acquired shares. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2025-04-28” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has received Phase 3 clinical trial plan approval from the Ministry of Food and Drug Safety (MFDS) of South Korea for CT-P51, a biosimilar candidate to Keytruda, targeting patients with metastatic non-squamous non-small cell lung cancer. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with a US-based pharmaceutical company valued at approx. KRW 737.3B (USD 513,959,800), representing 16.21% of its FY2024 consolidated revenue. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced a modification of listing to reduce 268,385 common shares following a share retirement, decreasing the total outstanding common shares to 222,989,898 shares, effective April 30, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Registration of Share Count…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to dispose of 1,575 treasury common shares (valued at approximately KRW 239.65M) by delivering them to option holders’ personal accounts following stock option exercises. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Treasury Share Count Adjustments…
Read More “[Disclosure] Celltrion (068270) – Treasury Share Disposal Decision / 2025-04-23” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed its provisional Q1 2025 consolidated financial results via fair disclosure, reporting revenue of KRW 1.298T (+37.11% YoY) and operating profit of KRW 486.7B (+119.92% YoY). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Provisional Earnings…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received approval from the U.S. FDA for a supplemental Biologics License Application (sBLA) securing interchangeability status for Yuflyma, its Humira biosimilar. This designation allows Yuflyma to be substituted for the reference product at the pharmacy level without the intervention of a prescribing physician. 📊 Key…